• Jinxin Fertility annual report for 2025 flagged a strategic shift toward intensive growth, with focus on quality and cash flow.
• Group completed 28,039 treatment cycles in 2025, reflecting a second-half recovery versus first half.
• China operations leaned on Chengdu strength, while Greater Bay Area repositioned around Shenzhen relocation and capacity expansion ahead of February 2026 opening.
• US business slowed expansion pace to prioritize cash generation, while positioning for California SB 729 insurance-driven demand starting Jan. 1, 2026.
• Board set a 3-year shareholder return framework, including RMB 100 million final dividend for 2025, with 50%-80% of annual adjusted EBITDA earmarked for dividends or buybacks in 2026-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jinxin Fertility Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260423-12119439), on April 23, 2026, and is solely responsible for the information contained therein.